Auto review: Maserati Ghibli a sedan that awakens the senses
Despite being more than a century old, it's an unfamiliar name which, when mentioned to most Americans, makes them smile as if you mentioned their secret, illicit love affair.
The 2014 Maserati Ghibli doesn't have much in common with the Ghibli coupe and convertible built from 1967 through 1973 and designed by Gioretto Giugiaro. Instead, this model shares its voluptuous curves with the Quattroporte. Like its larger sibling, the Ghibli has the glamorous appeal of a fashion supermodel and garners similar stares of longing from all who see it. The leather-and-wood-trimmed cabin is a sensual feast for the senses as only the Italians can produce. The feeling is enhanced by an instrument panel that's blessedly simple. There's no excess of buttons, knobs or gadgets. And the mammoth paddle shifters mounted to the steering column look as if they'd be at home in a Ferrari.
All Ghiblis start with rear-wheel-drive and a 345-horsepower twin-turbocharged 3.0-liter V-6 engine mated to an eight-speed automatic transmission. Care for all-wheel drive? Then you'll want the S Q4, with all-wheel drive, an extra 59 horses under the hood and a base price of $76,900.
The test vehicle gulped one gallon of premium fuel every 17 miles, but it was worth every drop since Ferrari handles the engines' final assembly.
Its aura is one of relaxed assurance, mixed in with a bit of quirkiness. After all, how many cupholders have you ever seen with a lighter in them? The Ghibli has it. And wait till you try using the electronic shifter; it takes a deft touch to master.
Who cares? You want precision? Buy German. The Ghibli offers something Mercedes-Benz, BMW and Audi can't: Amour.
There's little doubt that the Ghibli is distinctive, an Italian supermodel dressed down a bit for mass consumption and every bit as enticing and odd.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Wolf reverses Corbett, says deal between Highmark, UPMC doesn’t limit continuity of care to very ill
- Big banks’ levels of capital strong, Federal Reserve finds
- Americans see improved job market but a vulnerable economy, Pew poll finds
- IPO might test Etsy’s approach to commerce
- AbbVie to buy leukemia drugmaker Pharmacyclics for $21 billion
- Researchers: U.S. lacks proving ground for nuclear energy innovations
- Race toward bigger phones eases
- Worker productivity falls faster than estimated; labor costs rise
- Top residential, commercial deals of the week — March 1
- Impact fees garner support from state community leaders
- Stocks snap losing streak as ECB reveals stimulus start date